SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in ...

Core Insights - ResMed has launched new patient-centric products aimed at enhancing the therapy journey for sleep apnea patients, integrating digital wearables and generative AI for a personalized sleep health experience [2][4] Group 1: Product Innovations - The myAir™ app has been integrated with Apple and Android smartwatches, allowing users to monitor their CPAP therapy data easily [1][6] - A new generative AI-enabled sleep health assistant named Dawn provides 24/7 access to personalized guidance and information about sleep health and CPAP therapy [7] - The LUXE range of travel gear has been introduced, designed for CPAP users to facilitate therapy while traveling, featuring stylish and practical tote bags and backpacks [8] Group 2: Market Insights - ResMed's 2024 Global Sleep Survey revealed that 44% of Americans experience fewer than three good nights of sleep each week, highlighting a significant impact on quality of life [3] - The survey also indicated that 54% of respondents are interested in purchasing wearable devices with sleep-tracking capabilities, reflecting a growing focus on sleep health [3] Group 3: Patient Engagement - The myAir app has shown to significantly increase CPAP usage, with 87% of patients achieving therapy compliance through interactive coaching and nightly sleep data tracking [5] - New features in the myAir app include sleep staging integration, personalized coaching based on behavior science, and a holistic view of health metrics, all aimed at improving user engagement with CPAP therapy [6]

ResMed Inc (NYSE: RMD ) managed to deliver double-digit revenue and profit growths over the past 9 years despite being in a sector with single-digit revenue growth. This was because of its continuous acquisitions. BSc (Eng), MBA. Self-taught value investor with 2 decades of investing experience. Blogger at i4value.asia. The blog is on value investing through case studies where I analyze and value listed companies in the ASEAN and US regions. I have an exceptional perspective having served as a Board member ...

Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate cut since March 2020. ResMed shares tumbled after analysts said the likely label expansion of popular weight-loss drugs to treat sleep apnea could hurt demand for the company's devices. General Motors stock increased as the carmaker introduced adapters allowing drivers to power up GM EVs using Tesla's charging station network. Major U.S. equities indexes ended lower on Wednesday after ...

A looming threat from a very powerful rival could significantly dampen a key business for the company. Healthcare technology company ResMed's (RMD -5.12%) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, bearish outlook. That performance didn't look good against that of the S&P 500 index, which fell a comparatively light 0.3%. A change in recommendation for the worse Well before market open that day, Wolfe Resea ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is ResMed (NYSE: RMD ) , a fast-growing healthcare company. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the comp ...

ResMed Inc.'s (RMD) growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices. However, concerns loom over ResMed's escalating debt level and the adverse impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) company's shares have surged 66.9% compared with 16.9% growth of the industry. The S&P 500 composite rose 21.1% during ...

Learn more about ResMed's 2030 strategy to accelerate growth Join in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast link (available ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY. More information about this event, including access to the live, audio-only webca ...

Market Overview - The S&P 500 increased by 0.2% on August 27, ahead of Nvidia's earnings report and key economic data releases later in the week [1][2] - Major U.S. equity indexes, including the Nasdaq, also saw gains, with the Dow achieving a record high close [2] Company Performances - ResMed's shares surged by 7.3%, driven by a positive outlook for the sleep apnea devices market, which is expected to grow at a compound annual growth rate (CAGR) of 8.5% [3] - Insulet's shares rose by 6.6% following FDA approval of its Omnipod 5 insulin pump for type 2 diabetes, marking it as the first automated insulin delivery system approved for both type 1 and type 2 diabetes [4] - Travel industry stocks gained after Trip.com reported better-than-expected quarterly sales and profits, with Royal Caribbean Cruises, Norwegian Cruise Line, and Carnival seeing increases of 4.3%, 3.6%, and 2.7% respectively [5] Declining Stocks - Walgreens Boots Alliance experienced a 9.0% drop in shares after Eli Lilly announced a cheaper version of its weight-loss treatment, raising concerns about Walgreens' sales [6] - Paramount Global's shares fell by 7.2% after media executive Edgar Bronfman Jr. withdrew his acquisition proposal, leading to uncertainties about the company's future [7] - Martin Marietta Materials saw a 4.3% decline in shares, despite a price target increase from Morgan Stanley, due to insider share sales indicating potential lack of confidence [8]